Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
Jaguar Health Inc (JAGX)
Jaguar Health Inc (JAGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses

/CNW/ - Jaguar Health, Inc. (NASDAQ: JAGX), Filament Health Corp. (NEO: FH) (OTCQB: FLHLF) and One Small Planet, LLC today announced the formation of a...

JAGX : 0.6647 (+6.05%)
FLHLF : 0.0640 (-19.70%)
Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee to Assess Opportunities for Alliances, Mergers, and Acquisitions

Greg Divis departs from Jaguar's Board of Directors; Experienced business development executive Rachel Zolot Schwartz chairs new committee

JAGX : 0.6647 (+6.05%)
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, CA / ACCESSWIRE / July 1, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective June 27, 2022, the Company granted 60,000 restricted stock...

JAGX : 0.6647 (+6.05%)
Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China

License fees of $5.0 million, and up to $5.0 million in unregistered equity infusion, over next 24 months

JAGX : 0.6647 (+6.05%)
Jaguar Health Announces Online Availability of a Presentation on Short Bowel Syndrome (SBS) by Dr. Mohamad Miqdady at Elite Ped-GI Congress in Abu Dhabi

SAN FRANCISCO, CA / ACCESSWIRE / June 22, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that a presentation by Dr. Mohamad Miqdady on short bowel syndrome (SBS) at the Elite Ped-GI Congress,...

JAGX : 0.6647 (+6.05%)
Jaguar Animal Health Exhibiting at the June 23-25 American College of Veterinary Internal Medicine (ACVIM) Forum as Part of Ongoing Commercial Launch Activities for Canalevia-CA1

Canalevia®-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from...

JAGX : 0.6647 (+6.05%)
Jaguar Health Announces Publication of Onco'Zine Article Underscoring the Importance of Controlling Diarrhea in Cancer Patients

Diarrhea is also a prevalent side effect in dogs undergoing cancer treatment; managing diarrhea can be important to maintain successful cancer treatment in both humans and dogs

JAGX : 0.6647 (+6.05%)
Jaguar Health Reports Voting Results from 2022 Annual Meeting of Stockholders

All Proposals Approved

JAGX : 0.6647 (+6.05%)
Jaguar Health to Participate in BIO International Convention (BIO 2022)

Jaguar seeking partnering meetings at BIO 2022 related to the company's novel plant-based FDA-approved anti-secretory agent for cancer therapy-related diarrhea (CTD) and inflammatory bowel disease (IBD)...

JAGX : 0.6647 (+6.05%)
Jaguar Health and Filament Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental Health Indications

Drug Discovery Collaboration Will Leverage the Botanical Drug Development Expertise of Both Companies

JAGX : 0.6647 (+6.05%)
FLHLF : 0.0640 (-19.70%)
FH : 1.52 (+9.35%)

Barchart Exclusives

Nvidia: Down 10% From Last Week's High, is Now a Good Time to Buy?
The AI frenzy has set tech stocks on a price spurt when the market faces recessionary risks. Is Nvidia’s $1 trillion valuation an AI bubble or here to stay? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar